TG Therapeutics TGTX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's cash & equivalents?
- TG Therapeutics (TGTX) reported cash & equivalents of $442.21M in Q1 2026.
- How has TG Therapeutics's cash & equivalents changed year-over-year?
- TG Therapeutics's cash & equivalents increased by 234.7% year-over-year, from $132.14M to $442.21M.
- What is the long-term trend for TG Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), TG Therapeutics's cash & equivalents has grown at a -32.2% compound annual growth rate (CAGR), from $553.44M to $79.15M.
- What does cash & equivalents mean?
- The total amount of cash and highly liquid assets the company can access immediately.
- How do you interpret cash & equivalents?
- An increase suggests improved liquidity and financial flexibility, while a decrease may indicate high cash burn or significant capital deployment.
- How does cash & equivalents compare across companies?
- Biotech peers typically maintain high cash balances to fund multi-year clinical trials and commercialization efforts.